You just read:

Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer

News provided by

Foresee Pharmaceuticals Co., Ltd.

Feb 21, 2019, 05:30 ET